But of importance from a clinical perspective, it may be appropriate to treat these different tumour subtypes (ER- wtTP53 and ER+ mTP53) with the same therapeutic strategy using for example, IFN-γ directly, or with an agonist of the pathway. Here, IFNG is linked to neoplasm.